Coherus Oncology (CHRS) Capital Expenditures (2013 - 2025)

Coherus Oncology has disclosed Capital Expenditures across 13 years of filings, most recently posting $8.4 million for Q4 2025.

• In Q4 2025, Capital Expenditures changed N/A year-over-year to $8.4 million; the TTM figure through Dec 2025 stood at -$470.3 million (down 106.43% YoY), while the FY2025 annual figure was -$470.3 million, down 106.43% from the prior year.
• Capital Expenditures came in at $8.4 million for Q4 2025 at Coherus Oncology, up from -$483.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $8.4 million in Q4 2025 to a low of -$483.4 million in Q2 2025.
• Average Capital Expenditures over 5 years is -$43.4 million, with a median of $206500.0 recorded in 2021.
• Year-over-year, Capital Expenditures jumped 324.14% in 2022 and tumbled 123667.76% in 2024.
• Over 5 years, Capital Expenditures stood at $468000.0 in 2021, then plunged by 81.41% to $87000.0 in 2022, then sank by 60.92% to $34000.0 in 2023, then tumbled by 117747.06% to -$40.0 million in 2024, then surged by 120.94% to $8.4 million in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were $8.4 million in Q4 2025, -$483.4 million in Q2 2025, and $4.7 million in Q1 2025.